Skip to main content

Table 4 Clinical biomarkers and sputum differential counts by cohort at Screening/Baseline Visits

From: Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study

Cohorts

Healthy

Mild

Moderate

Severe

p-value***

n (blood/sputum)

30/20

52/32

55/38

51/40

 

FENO (ppb)*

NA

32.9 (+64.2/-16.9)

29.1 (+61.0/-13.9)

28.8 (+64.7/-12.9)

NA/0.59

bEOS, cells/μl*

112 (+218/-57)

178 (+347/-91)

197 (+435/-89)

210 (+452/-97)

0.0018/0.54

bNEU, 1000 cells/μl*

3.47 (+4.96/-2.42)

3.59 (+4.72/-2.74)

3.64 (+4.92/-2.69)

3.94 (+5.89/-2.63)

0.35/0.32

Serum IgE, RFU*

1.0 (+2.1/-0.7)

8.3 (+25.3/-6.2)

9.8 (+26.7/-7.2)

12.1 (+31.0/-8.7)

<0.0001/0.35

Sputum eosinophils, % of WBC*

0.38 (+0.78/-0.25)

1.12 (+5.38/-0.93)

3.12 (+13.62/-2.54)

2.70 (+12.27/-2.21)

<0.0001/0.033

Sputum lymphocytes, % of WBC**

1.16 (1.05)

1.29 (1.42)

0.98 (1.19)

0.94 (1.25)

0.64/0.48

Sputum macrophages, % of WBC**

44.57 (19.42)

50.20 (31.17)

32.10 (21.45)

43.04 (26.46)

0.031/0.019

Sputum neutrophils, % of WBC**

53.57 (20.06)

43.88 (30.90)

56.99 (26.13)

48.10 (25.52)

0.19/0.13

  1. *Geometric mean (asymmetric standard deviation) reported by cohort
  2. **Mean (standard deviation) reported by cohort
  3. ***p-value (ANOVA F-test) for differences across severity cohorts, including/excluding healthy control cohort (based on log-transformed data when geometric means reported)
  4. NA = not applicable (not measured in healthy cohort)